Heart Drug Wars: ESC Congress Delivers a Breakthrough and a Bust in Munich

Cytokinetics' aficamten scored a major win at the European Society of Cardiology Congress in Munich on Friday, with full Phase 3 data showing 53% of patients on the drug achieved meaningful improvements across at least three key disease areas — stamina, symptom relief, and heart strain — compared to just 13% on placebo in the 517-patient study. The company plans to submit for expanded FDA approval of Myqorzo by year-end, potentially doubling its market reach into...